AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25486369
Drug: Borderline B12
RxNorm normalized name: Coenzyme B12
DrugBank: Cobamamide (DB11191)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Borderline B12 concentrations (148 to 221 pmol/L)
Trial: 25486369
Drug: Low B12
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low B12 (<148 pmol/L)
Trial: 22475985
Drug: Buprenorphine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine plus ultra-low-dose naloxone (0.3 mg + 0.02 mg)
Trial: 22475985
Drug: Buprenorphine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine alone (0.3 mg)
Trial: 20532452
Drug: Erythromycin 500
RxNorm normalized name: erythromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 500 mg orally one hour prior to imaging
Trial: 16234574
Drug: Active 40
RxNorm normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Active 40 KHz ultrasound therapy delivered by a saline mist
Trial: 12399142
Drug: ketamine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketamine (0.3 mg/kg; intravenous)
Trial: 12399142
Drug: haloperidol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: haloperidol (2 mg) + ketamine (0.3 mg/kg; intravenous)
Trial: 7572966
Drug: Vaccine for
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine for Haemophilus influenzae type b (Hib)
Trial: 2301090
Drug: Metoprolol (Seloken)
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol (Seloken) administered once or twice daily
Trial: 31543373
Drug: n-3 PUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFA (2 g, ×2)
Trial: 31543373
Drug: Placebo (olive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (olive oil, 2 g ×2)
Trial: 31024122
Drug: Reduced receptor
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced receptor type‐specific actions of dopamine in women
Trial: 31024122
Drug: Reduced receptor
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced receptor type‐specific actions of dopamine in men
Trial: 23812551
Drug: Arginine-supplemented enteral
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine-supplemented enteral nutrition (9.0 g/L)
Trial: 21367943
Drug: Casein (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casein (20 g)
Trial: 21367943
Drug: Casein hydrolysate
RxNorm normalized name: casein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casein hydrolysate (20 g)
Trial: 19737620
Drug: Tiotropium (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium (18 mcg) once daily
Trial: 19737620
Drug: Ipratropium (26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipratropium (26 mcg)/Albuterol (206 mcg), 2 actuations 4 times daily
Trial: 17403721
Drug: C-reactive protein
RxNorm normalized name: C-reactive protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-reactive protein (CRP) levels in diabetic patients vs. non-diabetic patients in OPUS-TIMI 16 (9 mg/L vs. 7.8 mg/L, P = 0.002)
Trial: 17403721
Drug: MCP-1 levels
RxNorm normalized name: MCPA TRIISOPROPANOLAMINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCP-1 levels in diabetic patients vs. non-diabetic patients in OPUS-TIMI 16 (190.6 pg/mL vs. 170.8 pg/mL, P = 0.04)
Trial: 17403721
Drug: C-reactive protein
RxNorm normalized name: C-reactive protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-reactive protein levels in diabetic patients vs. non-diabetic patients in TACTICS-TIMI 18 (6.6 mg/L vs. 5.2 mg/L, P = 0.0005)
Trial: 17403721
Drug: Risk associated
RxNorm normalized name: HEPATITIS ASSOCIATED ANTIBODY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk associated with a 1 mmol/L increase in glucose among those with CRP greater than or equal to the median (HR 1.07, 95% CI 1.03-1.11) vs. those with CRP less than the median (HR 1.02, 95% CI 0.97-1.06)
Trial: 15110367
Drug: Cisatracurium 0.015
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium 0.015 mg.k(‐1)
Trial: 15110367
Drug: Rocuronium 0.09
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.09 mg.k(‐1)
Trial: 11255446
Drug: Donepezil 5
RxNorm normalized name: donepezil 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 5 mg/d followed by 10 mg/d
Trial: 8423906
Drug: Ticlopidine 250
RxNorm normalized name: ticlopidine 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine 250 mg twice a day
Trial: 8423906
Drug: Aspirin 650
RxNorm normalized name: aspirin 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 650 mg twice a day
Trial: 24731498
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics (n = 192)
Trial: 24731498
Drug: Antibiotics (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (n = 134)
Trial: 20588187
Drug: 0.6 mg/h
RxNorm normalized name: nitroglycerin 0.6 MG/HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg/h transdermal nitroglycerin (TGTN)
Trial: 20588187
Drug: 0.05 mg/h
RxNorm normalized name: fentanyl 0.05 MG/HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/h transdermal nitroglycerin (TGTN)
Trial: 20588187
Drug: Sublingual nitroglycerin
RxNorm normalized name: nitroglycerin Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual nitroglycerin and inhaled salbutamol
Trial: 18217157
Drug: Prasugrel 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 60 mg loading dose (LD) / 10 mg maintenance dose (MD)
Trial: 18841285
Drug: Clopidogrel 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 600 mg loading dose (LD) / 75 mg maintenance dose (MD)
Trial: 11371659
Drug: Combined immunoadsorption
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined immunoadsorption and intravenous immunoglobulins (n=17)
Trial: 11371659
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of immunoglobulins at a dose of 0.14 g/kg
Trial: 11371659
Drug: Immunoglobulin administration
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoglobulin administration
Trial: 2956870
Drug: Enoximone (MDL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone (MDL 17,043) 50, 75, 100, 150 or 200 mg (mean dose 1.46 +/- 0.16 mg/kg)
Trial: 30037519
Drug: NIPPV with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIPPV with nasal cannula (NC) at 15 L/min of oxygen
Trial: 23690996
Drug: Severity-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severity-based treatment protocols
Trial: 23690996
Drug: Treatment (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment (specific gene expression profiling)
Trial: 9411502
Drug: Dexamethasone therapy
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone therapy (0.4 mg/kg every 12 hours for 2 days, started 10 minutes before the first antibiotic dose)
Trial: 25546177
Drug: Sono-electro-magnetic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sono-electro-magnetic therapy
Trial: 21385862
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day of rosuvastatin added to 80 mg/day of valsartan (ARB)
Trial: 21385862
Drug: ARB monotherapy
RxNorm normalized name: revakinagene taroretcel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARB monotherapy (80 mg/day of valsartan)
Trial: 8690778
Drug: Dog and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dog and monkey sera used as blocking antibodies against mouse anti-hsCR1 monoclonal antibodies
Trial: 8690778
Drug: Mouse, rat,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mouse, rat, dog antibodies
Trial: 1930618
Drug: Biperiden 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biperiden 6 mg
Trial: 7049075
Drug: Topical poly(ICLC)
RxNorm normalized name: poly ICLC
DrugBank: Hiltonol (DB17293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical poly(ICLC)
Trial: 20391735
Drug: Fentanyl 2
RxNorm normalized name: fentanyl 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 2 mg/kg and Propofol 2 mg/kg (group PRO)
Trial: 20391735
Drug: Fentanyl 2
RxNorm normalized name: fentanyl 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 2 mg/kg and Sevoflurane 5% in a 1:2 mixture of oxygen and nitrous oxide (group SEVO)
Trial: 18165765
Drug: Subcutaneous alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous alemtuzumab (30 mg doses on days 0 and 1)
Trial: 15226321
Drug: docetaxel plus
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel plus thalidomide 200 mg orally each day
Trial: 15226321
Drug: docetaxel 30
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel 30 mg/m(2) intravenously every week for 3 consecutive weeks
Trial: 11566519
Drug: LEC removal
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEC removal from the entire anterior capsule (Group C)
Trial: 9631312
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate (RBC) 400 mg bid for 4 weeks plus amoxicillin 500 mg qid for 2 weeks
Trial: 9631312
Drug: RBC 400
RxNorm normalized name: Ultratag RBC KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC 400 mg bid for 4 weeks and placebo qid for 2 weeks
Trial: 9631312
Drug: Placebo bid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo bid for 4 weeks and amoxicillin 500 mg qid for 2 weeks
Trial: 14707892
Drug: Computer-assisted insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Computer-assisted insulin dose adjustment
Trial: 10513041
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg PYR
Trial: 2050326
Drug: S‐adenosyl‐L‐methionine, 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S‐adenosyl‐L‐methionine, 900 mg, administered via daily intravenous infusions for 20 days
Trial: 2050326
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered via daily intravenous infusions for 20 days
Trial: 6402356
Drug: Anticonvulsant medication
RxNorm normalized name: ANTICONVULSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticonvulsant medication (phenobarbitone) during pregnancy
Trial: 6402356
Drug: Anticonvulsant medication
RxNorm normalized name: ANTICONVULSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticonvulsant medication (multiple agents) during pregnancy
Trial: 6402356
Drug: Anticonvulsant medication
RxNorm normalized name: ANTICONVULSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticonvulsant medication during pregnancy
Trial: 30523758
Drug: NAB-paclitaxel 100
RxNorm normalized name: paclitaxel 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAB-paclitaxel 100 mg/m2 plus gemcitabine 1,000 mg/m2 (arm B)
Trial: 30523758
Drug: NAB-paclitaxel 125
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: NAB-paclitaxel 125 mg/m2 plus gemcitabine 1,000 mg/m2 (arm D)
Trial: 25901642
Drug: Keratin gel
RxNorm normalized name: gold keratinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Keratin gel
Trial: 25901642
Drug: Aqueous cream
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous cream (Control)
Trial: 24364085
Drug: Placebo (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (500 mL saline solution)
Trial: 16881463
Drug: Weight-bearing MWM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-bearing MWM treatment technique
Trial: 16881463
Drug: Non-weight-bearing MWM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-weight-bearing MWM treatment technique
Trial: 11170060
Drug: Interferon-alpha 2B
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha 2B therapy
Trial: 2458094
Drug: Methylphenidate hydrochloride
RxNorm normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate hydrochloride (intravenous administration)
Trial: 2458094
Drug: Methylphenidate hydrochloride
RxNorm normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate hydrochloride with beta-blocker or serotonin antagonist pretreatment
Trial: 29391008
Drug: Home fortification
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home fortification with iron-containing micronutrient powders (two different formulations)
Trial: 23275352
Drug: Liraglutide treatment
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide treatment for 12 weeks
Trial: 17681544
Drug: BRT (capnometry‐assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRT (capnometry‐assisted breathing therapy)
Trial: 17681544
Drug: Delayed‐treatment control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed‐treatment control group
Trial: 12602447
Drug: Temazepam (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temazepam (30 mg) administered before daytime sleep
Trial: 12602447
Drug: Placebo (lactose-filled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (lactose-filled capsule)
Trial: 10981531
Drug: Inhaled budesonide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide, 500 microg three times per day for 7 days (Group II)
Trial: 10981531
Drug: Nebulized budesonide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized budesonide, 500 microg twice per day for two months (Group III)
Trial: 10981531
Drug: Symptomatic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic treatment only (Group I)
Trial: 8915143
Drug: Sodium lauryl
RxNorm normalized name: sodium lauryl sulfate
DrugBank: Sodium lauryl sulfate (DB00815)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium lauryl sulphate (SLS) 1% aqueous solution
Trial: 18675974
Drug: Ultrashort flare
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrashort flare GnRH agonist combined with flexible multidose GnRH antagonist
Trial: 11957318
Drug: Polyester clothing
RxNorm normalized name: polyester-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyester clothing with low moisture absorption and high air permeability (B clothing)
Trial: 11957318
Drug: Cotton clothing
RxNorm normalized name: Cotton
DrugBank: Cotton (DB10707)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotton clothing with high moisture absorption and high air permeability (C clothing)
Trial: 7755827
Drug: Topical lidocaine-epinephrine
RxNorm normalized name: epinephrine / lidocaine Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine-epinephrine (TLE)
Trial: 2270298
Drug: Crystalline penicillin
RxNorm normalized name: Crystalline penicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalline penicillin (i.v. infusions for 10 days, daily dose of 20-24 mega U., combined with probenecid, followed by i.m. procaine penicillin in daily dose of 1.2 mega U., total dose 12-50 mega U.)
Trial: 2270298
Drug: Procaine penicillin
RxNorm normalized name: procaine penicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procaine penicillin (i.m. in daily dose of 1.2 mega U., total dose 24-60 mega U.)
Trial: 31002442
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavioural therapy pain management programme (CBT-PMP), six modules delivered once weekly.
Trial: 15635800
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 96% ethanol into the cyst after evaluation under ultrasonographic control
Trial: 9385973
Drug: Smooth implants
RxNorm normalized name: Derma-Smoothe FS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smooth implants
Trial: 18157310
Drug: Spherical orbital
RxNorm normalized name: barbital
DrugBank: Barbital (DB01483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spherical orbital implant
Trial: 18157310
Drug: Quad-motility orbital
RxNorm normalized name: barbital
DrugBank: Barbital (DB01483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quad-motility orbital implant
Trial: 18157310
Drug: Both spherical
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both spherical and quad-motility orbital implants
Trial: 15329588
Drug: Morphine 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.75 microg x kg(‐1) x min(‐1)
Trial: 11345288
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate (MF) nasal spray, 200 microg daily for 2 weeks
Trial: 9202835
Drug: Pentoxifylline 1200
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 1200 mg/day for 6 months
Trial: 7526102
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of GSNO starting 10 min before PTCA
Trial: 7526102
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (7 patients receiving standard treatment with aspirin, glyceryl trinitrate, and heparin)
Trial: 3299004
Drug: Org OD
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org OD 14 2.5 mg/day
Trial: 25917024
Drug: Aqueous povidone-iodine
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aqueous povidone-iodine solution (Group I)
Trial: 25917024
Drug: Alcoholic povidone-iodine
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcoholic povidone-iodine solution (Group II)
Trial: 20500100
Drug: Low-dose polytherapy
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose polytherapy (metformin 850 mg/day, flutamide 62.5 mg/day, pioglitazone 7.5 mg/day, ethinylestradiol 20 μg/day, drospirenone 3 mg/day)
Trial: 20500100
Drug: Low-dose polytherapy
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose polytherapy
Trial: 10357340
Drug: Dextromethorphan (DM)
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (DM) 40 mg IM administered 30 min before skin incision (Group B)
Trial: 10357340
Drug: Dextromethorphan (DM)
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (DM) 40 mg IM administered after gallbladder removal (Group A)
Trial: 10357340
Drug: Chlorpheniramine maleate
RxNorm normalized name: Chlorpheniramine Maleate
DrugBank: Chlorpheniramine (DB01114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine maleate (CPM) 20 mg IM administered 30 min before skin incision (Control group)
Trial: 1771934
Drug: omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprazole 40 mg/d for 4 weeks (n = 13)
Trial: 1771934
Drug: bismuth subsalicylate
RxNorm normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bismuth subsalicylate (BSS) 3 x 600 mg for 4 weeks (n = 12)
Trial: 1771934
Drug: triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triple therapy (BSS for 4 weeks, amoxicillin 3 x 750 mg and metronidazole 3 x 400 mg for 10 days) (n = 12)
Trial: 7137520
Drug: Terbutaline inhalations
RxNorm normalized name: terbutaline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline inhalations (5 doses)
Trial: 24894410
Drug: Freeze-dried broccoli
RxNorm normalized name: BLACKBERRY MESOCARP FREEZE DRIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Freeze-dried broccoli sprouts (90 mg of active sulforaphane, 15 capsules per day)
Trial: 24894410
Drug: Placebo (inactive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (inactive substances, mainly methylcellulose, same capsule size and portion distribution)
Trial: 22277664
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml kg(‐1) diluted raspberry syrup
Trial: 22277664
Drug: 7 ml
RxNorm normalized name: ethanol 7 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 ml kg(‐1) diluted raspberry syrup
Trial: 20625111
Drug: Enalapril (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (target dose 0.4 mg . kg(‐1) . d(‐1))